e104

E104 (compound 1), a selective TLR7 agonist, exhibits potent anticancer activity when delivered via antibody-drug conjugate (ADC) technology. It effectively activates mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) [1].

Cefclidin (Cefclidine) is a cephalosporin compound.

E3LigaseLigand-linker Conjugate 104 is a combination of an E3 ligase ligand and a linker (E3LigaseLigand-Linker Conjugates), consisting of Thalidomide and the associated linker. This conjugate functions as a Cereblon ligand to recruit CRBN protein and serves as a crucial intermediate for the synthesis of complete PROTACs molecules.

Luvesilocin (Example 6) is a tryptamine prodrug that converts into an active form acting as a 5HT2A receptor agonist in vivo. It is utilized for research concerning mental disorders.

BDC2.5 Mimotope 1040-63 is a biologically active peptide used in the investigation of type 1 diabetes (T1D), an autoimmune disease where T cells induce destruction of pancreatic islet β cells. This mimotope, originating from the TCR transgenic model (BDC2.5), facilitates the examination of antigen presentation mechanisms to islet autoantigen-specific T cells, contributing to the understanding of T cell-mediated beta-cell damage due to autoreactive T cell responses.

This is a effectively agonistic peptide (mimotope) for diabetogenic T cell clone BDC2.5. It can stimulate BDC2.5 cells with cells showing good response to this mimotope. 1040-31 peptide is specific for BDC2.5 TCR Tg+ (transgenic) T cells. This peptide is

BDC2.5 mimotope 1040-31 acetate is a effectively agonistic peptide (mimotope) for diabetogenic T cell clone BDC2.5. It can stimulate BDC2.5 cells with cells showing good response to this mimotope. 1040-31 peptide is specific for BDC2.5 TCR Tg+ (transgenic

This is a strongly agonistic peptide (mimotope) for diabetogenic T cell clone BDC2.5.

BDC2.5 mimotope 1040-51 is a mimotope peptide for the diabetogenic T cell clone BDC2.5, isolated from non-obese diabetic (NOD) mice. This effectively agonistic peptide prompts T cells from prediabetic and diabetic NOD mice to respond to BDC2.5 mimotope peptides.